Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
| Name (Synonyms) | Correlation | |
|---|---|---|
| drug1407 | Ensifentrine Dose 1 Wiki | 1.00 |
| drug2982 | Placebo pMDI Wiki | 1.00 |
| Name (Synonyms) | Correlation | |
|---|---|---|
| D045169 | Severe Acute Respiratory Syndrome NIH | 0.04 |
| D018352 | Coronavirus Infections NIH | 0.04 |
| Name (Synonyms) | Correlation |
|---|
Navigate: Correlations HPO
There is one clinical trial.
The COVID -19 pandemic has reduced endoscopy services to an average of 83% producing a significant economic impact on endoscopy units worldwide. Endoscopy as an aerosol-generating procedure requires endoscopy units to allow 12 cycles of air exchange per hour, equivalent to 20 minutes, between patients, to reduce medical risk exposure. Planning strategies to facilitate economic reactivation of endoscopy services in a responsible manner, maintaining adequate security measures for both patients and healthcare personnel is currently a major challenge. Serial endoscopic interventions as esophagogastroduodenoscopy (EGD) and colonoscopy are commonly performed during the same sedation time. Estimated times for quality inspection in the upper digestive tract and the colon, are 7 and 6 minutes, respectively. In addition, time to reach the cecum and to set up the following procedure increase not only procedure time but SARS-CoV-2 exposure to healthcare personnel. Performing these two procedures simultaneously by two endoscopists would considerably reduce procedure time while increasing the number of patients evaluated in one day, especially in the period of service reactivation. There are no studies comparing simultaneous EGD and colonoscopy procedures and, serial procedures. This study aims to determine differences in procedures times between simultaneous EGD-colonoscopy and conventional serial EGD-colonoscopy as an alternative to improve the number of procedures/hour/unit during the COVID-19 era.
Description: Time elapsed in minutes between the starting of the first procedure and the ending time of the second procedure in the serial arm or both procedures in the simultaneous arm.
Measure: Procedures time Time: Time elapsed in minutes between the starting of the first procedure and the ending time of the second procedure in the serial arm or both procedures in the simultaneous arm.Description: Time elapsed in minutes between the end of the first procedure and the starting of the second procedure (only applies in serial arm)
Measure: Interprocedure time Time: Time elapsed in minutes between the end of the first procedure and the starting of the second procedure (only applies in serial arm)Description: Time taken in minutes to inspect the entire upper GI mucosa according to the complete photodocumentation method proposed by Emura et al.
Measure: Upper GI inspection time Time: Time taken in minutes to inspect the entire upper GI mucosa according to the complete photodocumentation method proposed by Emura et al.Description: Time elapsed in minutes between the cecum and the lower rectum used to inspect the colorectal mucosa
Measure: Colonoscopy withdrawal time Time: Time elapsed in minutes between the cecum and the lower rectum used to inspect the colorectal mucosaDescription: Time elapsed in minutes to reach the cecum
Measure: Colonoscopy insertion time Time: Time elapsed in minutes to reach the cecumDescription: Time elapsed in minutes between the insertion of the gastroscope into the mouth and the extraction from the mouth
Measure: EGD time Time: Time elapsed in minutes between the insertion of the gastroscope into the mouth and the extraction from the mouthDescription: Time elapsed in minutes between the insertion of the colonoscope into the lower rectum and the extraction from the lower rectum
Measure: Colonoscopy time Time: Time elapsed in minutes between the insertion of the colonoscope into the lower rectum and the extraction from the lower rectumDescription: Amount in mg of Propofol used during EGD
Measure: Propofol used in EGD Time: Amount in mg of Propofol used during EGDDescription: Amount in mg of Propofol used during colonoscopy
Measure: Propofol used in colonoscopy Time: Amount in mg of Propofol used during colonoscopyDescription: Amount of Propofol in mg used fro procedures in the simultaneous arm.
Measure: Propofol used in EGD and colonoscopy Time: Amount of Propofol in mg used fro procedures in the simultaneous armDescription: Measurement of pCO2 by the percutaneous transducer at 5 minutes prior and 5, 10 during procedures and 5 and 10 minutes minutes after completing the last procedure.
Measure: percutaneous pCO2 Time: Measurement of pCO2 by the percutaneous transducer at 5 minutes prior and 5, 10 during procedures and 5 and 10 minutes minutes after completing the last procedure.Description: Measurement of pO2 by the percutaneous transducer at 5 minutes prior and 5, 10 during procedures and 5 and 10 minutes minutes after completing the last procedure.
Measure: percutaneous pO2 Time: Measurement of pO2 by the percutaneous transducer at 5 minutes prior and 5, 10 during procedures and 5 and 10 minutes minutes after completing the last procedure.Description: Change of patient's position during colonoscopy. Yes or No answer
Measure: Position change 1 Time: During colonoscopyDescription: If occurred, how many times the position changed. Numerical variable.
Measure: Position change 2 Time: During olonoscopyDescription: Nausea, drowsiness, and dizziness are scored by patients using a scale from 1 to 5 (1: None, 2: Mild, 3: Moderate, 4: Severe, and 5: Extreme).
Measure: Post procedure symptoms survey related to colonoscopy Time: 20 minutes after the last procedure and after 24 hoursDescription: Abdominal pain, bloating, and pharyngeal pain are scored by patients using a scale from 1 to 5 (1: None, 2: Mild, 3: Moderate, 4: Severe, and 5: Extreme).
Measure: Post procedure symptoms survey related to sedation Time: 20 minutes after the last procedure and after 24 hoursAlphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports